Military Technology

After listening to Qin Yongchuan's introduction, Wu Hao, Zhang Jun and the others couldn't help but nodded. If this technology can really be applied, it will definitely benefit many patients and save many lives.

When will this technology enter clinical trials? Zhang Jun still smelled an issue that he was more concerned about.

Qin Yongchuan smiled and replied: "At present, we have completed the technical safety demonstration of this biological drug. Next, we will enter animal testing to further test the efficacy and safety of this drug. If these are all If there are no problems, we will obtain the relevant clinical trial approval documents as soon as possible and then start the initial clinical trial work.

We plan to use two to three years of clinical trials to fully verify the efficacy and safety of this drug, and then start applying for relevant marketing. "

Hearing Qin Yongchuan's answer, Wu Hao smiled and nodded and said: "In recent years, with the continuous improvement of people's material life, physical health has become the focus of everyone's concern. People are increasingly dissatisfied with the current level of medical technology. Eager to obtain better medical resources and medical technical services.

Therefore, in recent years, the state has attached great importance to the pharmaceutical industry, and its support has been increasing. For some scientific research-based medical technology research enterprises, the state has also introduced a series of related preferential support policies, such as tax exemptions, scientific research funding subsidies, fund support and a series of measures.

It is hoped that a good research and development environment can be created so that domestic medical technology research enterprises can thrive quickly. Break the monopoly of foreign pharmaceutical giants in the field of cutting-edge drug technology and embark on a new era of scientific research with our own characteristics.

In order to promote more and better drugs to be successfully put on the market, provide health services to patients, and save more patients. Relevant departments have also provided great support in drug approval.

So regarding this, I suggest you strengthen communication and cooperation with relevant departments. This will help you carry out relevant research work, especially clinical trials and subsequent new drug launches.

In this way, our drug for treating Helicobacter pylori has received strong support from relevant departments and has now entered the approval stage before new drugs are launched on the market. If everything goes well, it will be approved before this fall and go on the market smoothly. "

After hearing Wu Hao's words, everyone present became excited. You know, this drug has not been developed for a long time. I did not expect it to be approved and marketed so quickly. This undoubtedly gave everyone present a great incentive, in accordance with the current relevant regulations. All scientific researchers participating in the project will receive a portion of the project’s market revenue as dividends. Although no one has a small share, if this technology has good market benefits, then they can also get a lot of money.

As for this new superbug drug that treats Helicobacter pylori infection in the stomach, based on the current efficacy of clinical trials, once it is launched on the market, it will definitely be welcomed by hospitals and patients. If it can be promoted on a large scale, the researchers involved in the research and development of this drug will be able to share a considerable amount of money. That's why everyone present was so surprised and excited when they heard these words.

Surprised at such a short period of time, I was naturally excited to think about how much money they could get if their drug could be put on the market.

You can rest assured that we have been maintaining close communication and contact with relevant departments in this regard. It's just that there are still some flaws in this technology, so we plan to polish it carefully before considering these things. Qin Yongchuan explained to Wu Hao.

When Wu Hao heard what Qin Yongchuan said, he naturally said nothing more, and Qin Yongchuan immediately led everyone to continue the visit.

"The research work in this area is mainly carried out on some basic diseases. Although there are already some very effective and remarkable drugs on the market. However, in our opinion, these drugs more or less exist some problems.

Therefore, we have selected some diseases for in-depth study to explore whether there are better technologies to apply treatment to achieve better results. Just like what you learned about myopia treatment technology before, there are many vision correction technologies on the market, but these only allow people to see things clearly and do not completely cure myopia, hyperopia, astigmatism, and strabismus.

So we are exploring whether there is a permanent way to let people say goodbye to their eyes and restore normal vision. At present, our research in this area has made great progress, and this technology will also be prepared to enter the clinical trial stage as planned.

And here, this is a gastrointestinal drug we are studying. There are many gastrointestinal drugs currently available, and many of them have good therapeutic effects on gastrointestinal diseases. However, these drugs also have serious side effects and are not suitable for long-term use.

However, gastrointestinal disease is a very difficult disease and can easily turn into a chronic disease. It usually requires a long treatment period, and the curative effect is not that significant, and it is very easy to relapse.

In our lives, many people suffer from gastrointestinal diseases, some of which are old diseases. They have been sick for several years, ten years, or even decades.

This is certainly related to people's attention and non-standard treatment, but it also has a lot to do with current drugs.

For example, many drugs used to treat gastrointestinal diseases can cause a lot of damage to other organs and tissues. For example, long-term medication can cause damage to metabolic organs such as the liver and kidneys. It can even cause damage to the gastrointestinal tissue itself. For example, long-term use of some proton inhibitors is likely to cause some damage to the gastrointestinal tract and increase the risk of cancer. Long-term use of some bismuth and aluminum agents can even produce heavy metals, which can cause damage to the brain.

Therefore, we are exploring whether there is a new drug that has fewer side effects, is gentler, and is suitable for long-term use. "

Speaking of this, Qin Yongchuan smiled at everyone and said: "Many people may think that this drug should be very simple, and have listed many similar drugs. But in fact, it is very difficult to research such drugs.

To develop a drug that is effective against the disease, does no harm to other organs of the body, and can be reused for a long time, this means that several huge problems with the drug must be solved in order to obtain a drug that is close to perfect. Drug.

However, to achieve this goal, it is not easy to develop such a perfect drug. "